A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease

FASEB Journal

Volumn 24, Issue 11, 2010, Pages 4459-4466

  Kithcart, Aaron P ^a   Cox, Gina M ^a   Sielecki, Thais ^b   Short, Abigail ^a   Pruitt, James ^b   Papenfuss, Tracey ^a   Shawler, Todd ^a   Gienapp, Ingrid ^a   Satoskar, Abhay R ^a   Whitacre, Caroline C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Cytokine PharmaSciences Inc   (United States)

Author keywords

Blood brain barrier; Experimental autoimmune encephalomyelitis; Multiple sclerosis

Indexed keywords

ANTIINFLAMMATORY AGENT; CPSI 1306; CPSI 2705; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; MACROPHAGE MIGRATION INHIBITION FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNOCOMPETENT CELL; LYMPHOCYTE PROLIFERATION; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION REGULATION; ISOXAZOLES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPINAL CORD; VASCULAR CELL ADHESION MOLECULE-1;

ANIMALIA; MUS;

EID: 78649849360     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-162347     Document Type: Article

References (39)

1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., and Weinshenker, B. G. (2000) Multiple sclerosis. N. Engl. J. Med. 343, 938-952
2. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mork, S., and Bo, L. (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285
3. Chou, Y. K., Bourdette, D. N., Offner, H., Whitham, R., Wang, R. Y., Hashim, G. A., and Vandenbark, A. A. (1992) Frequency of T cells specific for myelin basic protein and myelin proteo-lipid protein in blood and cerebrospinal fluid in multiple sclerosis. J. Neuroimmunol. 38, 105-113
4. Wingerchuk, D. M., Lucchinetti, C. F., and Noseworthy, J. H. (2001) Multiple sclerosis: current pathophysiological concepts. Lab. Invest. 81, 263-281
5. Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I., Wallstrom, E., Khademi, M., Oturai, A., Ryder, L. P., Saarela, J., Harbo, H. F., Celius, E. G., Salter, H., Olsson, T., and Hillert, J. (2007) Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39, 1108-1113
6. Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop, A., Caillier, S. J., Ban, M., Goris, A., Barcellos, L. F., Lincoln, R., McCauley, J. L., Sawcer, S. J., Compston, D. A., Dubois, B., Hauser, S. L., Garcia-Blanco, M. A., Pericak-Vance, M. A., and Haines, J. L. (2007) Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39, 1083-1091
7. Hafler, D. A., Compston, A., Sawcer, S., Lander, E. S., Daly, M. J., De Jager, P. L., de Bakker, P. I., Gabriel, S. B., Mirel, D. B., Ivinson, A. J., Pericak-Vance, M. A., Gregory, S. G., Rioux, J. D., McCauley, J. L., Haines, J. L., Barcellos, L. F., Cree, B., Oksenberg, J. R., and Hauser, S. L. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851-862
8. McFarland, H. F., and Martin, R. (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913-919
9. Racke, M. K. (2008) The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 21(Suppl. 1), S9-S18
10. Peterson, J. W., and Trapp, B. D. (2005) Neuropathobiology of multiple sclerosis. Neurol. Clin. 23, 107-129, vi-vii
11. Niino, M., Ogata, A., Kikuchi, S., Tashiro, K., and Nishihira, J. (2000) Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J. Neurol. Sci. 179, 127-131
12. David, J. R. (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U. S. A. 56, 72-77
13. Popa, C., van Lieshout, A. W., Roelofs, M. F., Geurts-Moespot, A., van Riel, P. L., Calandra, T., Sweep, F. C., and Radstake, T. R. (2006) MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine 36, 51-56
14. Zernecke, A., Bernhagen, J., and Weber, C. (2008) Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117, 1594-1602
15. Meyer-Siegler, K. L., Vera, P. L., Iczkowski, K. A., Bifulco, C., Lee, A., Gregersen, P. K., Leng, L., and Bucala, R. (2007) Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 8, 646-652
16. Bozza, M., Satoskar, A. R., Lin, G., Lu, B., Humbles, A. A., Gerard, C., and David, J. R. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341-346
17. De Jong, Y. P., Abadia-Molina, A. C., Satoskar, A. R., Clarke, K., Rietdijk, S. T., Faubion, W. A., Mizoguchi, E., Metz, C. N., Alsahli, M., ten Hove, T., Keates, A. C., Lubetsky, J. B., Farrell, R. J., Michetti, P., van Deventer, S. J., Lolis, E., David, J. R., Bhan, A. K., and Terhorst, C. (2001) Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. 2, 1061-1066
18. Rodriguez-Sosa, M., Rosas, L. E., David, J. R., Bojalil, R., Satoskar, A. R., and Terrazas, L. I. (2003) Macrophage migration inhibitory factor plays a critical role in mediating protection against the helminth parasite Taenia crassiceps. Infect. Immun. 71, 1247-1254
19. Satoskar, A. R., Bozza, M., Rodriguez Sosa, M., Lin, G., and David, J. R. (2001) Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 69, 906-911
20. Flores, M., Saavedra, R., Bautista, R., Viedma, R., Tenorio, E. P., Leng, L., Sanchez, Y., Juarez, I., Satoskar, A. A., Shenoy, A. S., Terrazas, L. I., Bucala, R., Barbi, J., Satoskar, A. R., and Rodriguez-Sosa, M. (2008) Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J. 22, 3661-3671
21. Kleemann, R., and Bucala, R. (2010) Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm. 2010, 610479
22. Rosengren, E., Bucala, R., Aman, P., Jacobsson, L., Odh, G., Metz, C. N., and Rorsman, H. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2, 143-149
23. Weiser, W. Y., Temple, P. A., Witek-Giannotti, J. S., Remold, H. G., Clark, S. C., and David, J. R. (1989) Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U. S. A. 86, 7522-7526
24. Kleemann, R., Kapurniotu, A., Frank, R. W., Gessner, A., Mischke, R., Flieger, O., Juttner, S., Brunner, H., and Bernhagen, J. (1998) Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. 280, 85-102
25. Matsunaga, J., Sinha, D., Pannell, L., Santis, C., Solano, F., Wistow, G. J., and Hearing, V. J. (1999) Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. 274, 3268-3271
26. Bernhagen, J., Krohn, R., Lue, H., Gregory, J. L., Zernecke, A., Koenen, R. R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S. R., Bucala, R., Hickey, M. J., and Weber, C. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13, 587-596
27. Schober, A., Bernhagen, J., and Weber, C. (2008) Chemokine-like functions of MIF in atherosclerosis. J. Mol. Med. 86, 761-770
28. Miller, A. (1997) Current and investigational therapies used to alter the course of disease in multiple sclerosis. South. Med. J. 90, 367-375
29. Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., and Sandrock, A. W. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910
30. Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jager, H. R., and Clifford, D. B. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933
31. Fitzgerald, D. C., Ciric, B., Touil, T., Harle, H., Grammatikopolou, J., Das Sarma, J., Gran, B., Zhang, G. X., and Rostami, A. (2007) Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 179, 3268-3275
32. Powell, N. D., Papenfuss, T. L., McClain, M. A., Gienapp, I. E., Shawler, T. M., Satoskar, A. R., and Whitacre, C. C. (2005) Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J. Immunol. 175, 5611-5614
33. Aroca, P., Solano, F., Garcia-Borron, J. C., and Lozano, J. A. (1991) Specificity of dopachrome tautomerase and inhibition by carboxylated indoles: considerations on the enzyme active site. Biochem. J. 277(Pt. 2), 393-397
34. Denkinger, C. M., Denkinger, M., Kort, J. J., Metz, C., and Forsthuber, T. G. (2003) In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. 170, 1274-1282
35. Stromnes, I. M., and Goverman, J. M. (2006) Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1, 1810-1819
36. Engelhardt, B. (2006) Regulation of immune cell entry into the central nervous system. Results Probl. Cell Differ. 43, 259-280
37. Bo, L., Peterson, J. W., Mork, S., Hoffman, P. A., Gallatin, W. M., Ransohoff, R. M., and Trapp, B. D. (1996) Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55, 1060-1072
38. Mottet, C., Uhlig, H. H., and Powrie, F. (2003) Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 170, 3939-3943
39. Sanchez-Zamora, Y., Terrazas, L. I., Vilches-Flores, A., Leal, E., Juarez, I., Whitacre, C., Kithcart, A., Pruitt, J., Sielecki, T., Satoskar, A. R., and Rodriguez-Sosa, M. (2010) Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24, 2583-2590